Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies.
Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies.
复制标题
DOI：
10.1080/22221751.2022.2030200
复制
发表时间：
2022-12
影响因子：
13.2
通讯作者：
Wang P
中科院分区：
文献类型：
--
作者：
Wang X;Zhao X;Song J;Wu J;Zhu Y;Li M;Cui Y;Chen Y;Yang L;Liu J;Zhu H;Jiang S;Wang P
SARS-CoV-2的大规模和快速传播导致了几种令人关注的病毒变体(VOC)的出现，最近的一种是B.1.1.529(Omicron)，它积累了大量的尖峰突变，引发了人们对这种新发现的变体可能逃脱当前可用的疫苗和治疗性抗体的担忧。利用基于VSV的伪病毒，我们发现Omicron变异体对恢复期或两剂灭活全病毒疫苗(BBIBP-CorV)免疫的人的血清具有明显的中和抗性。然而，同源灭活疫苗增强剂或含有蛋白质亚单位疫苗的异源增强剂(ZF2001)显著增加了WT和OMICRON变种的中和滴度。此外，在第三剂疫苗接种后第14天，奥美康的中和抗体滴度下降幅度小于恢复期或只接种两剂疫苗的人，表明同源或异种佐剂可以减少奥米克隆的中和逃逸。此外，我们还检测了一组17株SARS-CoV-2单抗。奥米克龙抵抗8个授权/批准的单抗中的7个，以及大多数其他针对RBD和NTD上不同表位的单抗。综上所述，我们的结果表明了推进加强疫苗接种以对抗新出现的SARS-CoV-2变种的紧迫性。
The massive and rapid transmission of SARS-CoV-2 has led to the emergence of several viral variants of concern (VOCs), with the most recent one, B.1.1.529 (Omicron), which accumulated a large number of spike mutations, raising the specter that this newly identified variant may escape from the currently available vaccines and therapeutic antibodies. Using VSV-based pseudovirus, we found that Omicron variant is markedly resistant to neutralization of sera from convalescents or individuals vaccinated by two doses of inactivated whole-virion vaccines (BBIBP-CorV). However, a homologous inactivated vaccine booster or a heterologous booster with protein subunit vaccine (ZF2001) significantly increased neutralization titers to both WT and Omicron variant. Moreover, at day 14 post the third dose, neutralizing antibody titer reduction for Omicron was less than that for convalescents or individuals who had only two doses of the vaccine, indicating that a homologous or heterologous booster can reduce the Omicron escape from neutralizing. In addition, we tested a panel of 17 SARS-CoV-2 monoclonal antibodies (mAbs). Omicron resists seven of eight authorized/approved mAbs, as well as most of the other mAbs targeting distinct epitopes on RBD and NTD. Taken together, our results suggest the urgency to push forward the booster vaccination to combat the emerging SARS-CoV-2 variants.
登录
查看更多内容
影响因子：
13.2
作者：
Ai J;Zhang H;Zhang Y;Lin K;Zhang Y;Wu J;Wan Y;Huang Y;Song J;Fu Z;Wang H;Guo J;Jiang N;Fan M;Zhou Y;Zhao Y;Zhang Q;Liu Q;Lv J;Li P;Qiu C;Zhang W
通讯作者：
Zhang W
DOI：
10.1016/s2213-2600(21)00559-2
发表时间：
2022-03
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Burki TK
通讯作者：
Burki TK
影响因子：
16.6
作者：
Kim C;Ryu DK;Lee J;Kim YI;Seo JM;Kim YG;Jeong JH;Kim M;Kim JI;Kim P;Bae JS;Shim EY;Lee MS;Kim MS;Noh H;Park GS;Park JS;Son D;An Y;Lee JN;Kwon KS;Lee JY;Lee H;Yang JS;Kim KC;Kim SS;Woo HM;Kim JW;Park MS;Yu KM;Kim SM;Kim EH;Park SJ;Jeong ST;Yu CH;Song Y;Gu SH;Oh H;Koo BS;Hong JJ;Ryu CM;Park WB;Oh MD;Choi YK;Lee SY
通讯作者：
Lee SY
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
影响因子：
13.2
作者：
Zhang L;Li Q;Liang Z;Li T;Liu S;Cui Q;Nie J;Wu Q;Qu X;Huang W;Wang Y
通讯作者：
Wang Y